Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jun;201(5):813-823.
doi: 10.1111/bjh.18782. Epub 2023 Apr 3.

Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients

Rhea Suribhatla  1 , Thomas Starkey  2 , Maria C Ionescu  3 , Antonio Pagliuca  4 , Alex Richter  5 , Lennard Y W Lee  2   6
Affiliations
Meta-Analysis

Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients

Rhea Suribhatla et al. Br J Haematol. 2023 Jun.

Abstract

Immunocompromised patients, such as those with a haematological malignancy, are at higher risk of SARS-CoV-2 infection, severe outcomes and mortality. Tixagevimab/cilgavimab is a monoclonal antibody combination which binds to the SARS-CoV-2 spike protein. The PROVENT phase III clinical trial reported that tixagevimab/cilgavimab prophylaxis significantly reduced the risk of COVID-19 infection in immunocompromised participants. However, the trial was conducted before the Omicron variant became prevalent. This systematic review and meta-analysis provide an up-to-date summary of the real-world effectiveness of tixagevimab/cilgavimab in immunocompromised patients, including patients with haematological malignancies. Clinical studies from 1 January 2021 to 1 October 2022, which reported breakthrough COVID-19 infections after tixagevimab/cilgavimab, were included. COVID-19-related hospitalisations, intensive care admissions and mortality were also assessed. A meta-analysis was performed to ascertain overall clinical effectiveness. Eighteen studies, with 25 345 immunocompromised participants, including 5438 patients with haematological pathologies, were included in the review. The overall clinical effectiveness of tixagevimab/cilgavimab against COVID-19 breakthrough infection, hospitalisation, intensive care admission and COVID-19-specific mortality was 40.54%, 66.19%, 82.13% and 92.39%, respectively. This review highlights the clinical effectiveness of tixagevimab/cilgavimab at reducing COVID-19 infection and severe outcomes for immunosuppressed individuals, including patients with a haematological malignancy, during the Omicron-predominant era. Real-world studies are important to provide ongoing certainty of the clinical benefit for immunocompromised patients against new SARS-CoV-2 variants.

Keywords: COVID-19; SARS-CoV-2; efficacy; immunocompromised; tixagevimab/cilgavimab.

PubMed Disclaimer

References

REFERENCES

    1. Kearns P, Siebert S, Willicombe M, Gaskell C, Kirkham A, Pirrie S, et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity-the OCTAVE Trial. 2021. http://dx.doi.org/10.2139/ssrn.3910058
    1. Why the Government should postpone lifting restrictions on June 21|Blood Cancer UK. https://bloodcancer.org.uk/news/were-calling-on-the-government-to-postpo... 2021.
    1. Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20:e1004086. https://doi.org/10.1371/journal.pmed.1004086
    1. Hippisley-Cox J, Khunti K, Sheikh A, Nguyen-Van-Tam J, Coupland C. QCovid 4-predicting risk of death or hospitalisation from COVID-19 in adults testing positive for SARS-CoV-2 infection during the omicron wave in England. MedRxiv. 2022. https://doi.org/10.1101/2022.08.13.22278733
    1. The OpenSAFELY Collaborative, Nab L, Parker EPK, Andrews CD, Hulme WJ, Fisher L, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England. medRxiv. 2022. https://doi.org/10.1101/2022.07.30.22278161

Publication types

Supplementary concepts

LinkOut - more resources